PRS by factors other than initial treatment regimen (n = 272)
| Characteristic . | 3-year postrelapse survival ± SE % (n) . | Log-rank P . |
|---|---|---|
| Timing from diagnosis, mo | ||
| < 36 | 30.0 ± 3.7 (190) | < .0001 |
| ≥ 36 | 57.8 ± 6.4 (82) | |
| Site | ||
| All | 38.1 ± 3.3 (272) | |
| Marrow (±EMD) | 29.7 ± 3.7 (186) | < .0001 |
| Isolated CNS | 52.2 ± 7.4 (66) | |
| Other isolated EMD | 68.2 ± 11.6 (20) | |
| Sex | ||
| Male | 38.2 ± 4.2 (173) | .92 |
| Female | 37.9 ± 5.4 (99) | |
| Age at initial diagnosis, y | ||
| 1-9 | 48.6 ± 5.3 (106) | .001 |
| 10-15 | 35.4 ± 5.0 (132) | |
| 16-20 | 14.7 ± 6.8 (34) | |
| Lineage | ||
| B | 40.5 ± 3.9 (193) | .09 |
| T | 29.2 ± 8.2 (46) |
| Characteristic . | 3-year postrelapse survival ± SE % (n) . | Log-rank P . |
|---|---|---|
| Timing from diagnosis, mo | ||
| < 36 | 30.0 ± 3.7 (190) | < .0001 |
| ≥ 36 | 57.8 ± 6.4 (82) | |
| Site | ||
| All | 38.1 ± 3.3 (272) | |
| Marrow (±EMD) | 29.7 ± 3.7 (186) | < .0001 |
| Isolated CNS | 52.2 ± 7.4 (66) | |
| Other isolated EMD | 68.2 ± 11.6 (20) | |
| Sex | ||
| Male | 38.2 ± 4.2 (173) | .92 |
| Female | 37.9 ± 5.4 (99) | |
| Age at initial diagnosis, y | ||
| 1-9 | 48.6 ± 5.3 (106) | .001 |
| 10-15 | 35.4 ± 5.0 (132) | |
| 16-20 | 14.7 ± 6.8 (34) | |
| Lineage | ||
| B | 40.5 ± 3.9 (193) | .09 |
| T | 29.2 ± 8.2 (46) |
EMD indicates extramedullary disease; and CNS, central nervous system.